Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of post-traumatic stress disorder
3.2.1.2 Growing awareness about mental health issues
3.2.1.3 Technological advancements in treatment options
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Key therapies for PTSD treatment
3.6.1 Cognitive behavioral therapy (CBT)
3.6.2 Eye movement desensitization and reprocessing (EMDR)
3.6.3 Exposure therapy
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 GAP analysis
3.10 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Antidepressants
5.3 Antipsychotics
5.4 Anti-anxiety
5.5 Other drug classes
Chapter 6 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Adult
6.3 Geriatrics
6.4 Pediatrics
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacy
7.3 Brick and mortar
7.4 E-commerce
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AstraZeneca Plc
9.2 Aurobindo Pharma Limited
9.3 Bionomics
9.4 Camber Pharmaceuticals, Inc.
9.5 Eli Lilly and Company
9.6 GSK plc
9.7 H. Lundbeck A/S
9.8 Jazz Pharmaceuticals plc
9.9 Johnson & Johnson Services, Inc.
9.10 Lupin Pharmaceuticals, Inc.
9.11 Merck & Co., Inc.
9.12 Novartis AG
9.13 Otsuka Pharmaceutical Co., Ltd.
9.14 Pfizer, Inc.
9.15 Takeda Pharmaceutical Company Limited
